Strides receives USFDA approval for Triamcinolone Acetonide Cream

Product approval from flagship facility in Bangalore
To be marketed by Strides Pharma Inc. in the US market

Bangalore, 13 February, 2019 Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. from the United States Food & Drug Administration (US FDA). The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. is approximately US$ 55 Mn. The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 86 cumulative ANDA filings with USFDA of which 56 ANDAs have been approved including 12 approvals received in FY 19.

About Triamcinolone Acetonide Cream

Triamcinolone Acetonide Cream is used to treat a variety of skin conditions including treatment of eczema, dermatitis, allergies, rash and helps in reducing swelling, itching, and redness that can occur in these types of conditions.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India- Bangalore (two sites), Pondicherry, and Chennai, Singapore, Italy- Milan, and Kenya- Nairobi. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badree Komandur, Executive Director - Finance +91 80 6784 0747</td>
<td>K Srinivas Reddy: +91 90005 27213 <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
</tbody>
</table>
**Investor Relations:**
Kannan. N: +91 98450 54745  
Vikesh Kumar: +91 80 6784 0827  
Sandeep Baid : +91 80 6784 0791  
Email: Sandeep.baid@strides.com

**Strides Pharma Science Limited**  
(Formerly Strides Shasun Limited)  
CIN : L24230MH1990PLC057062  
Regd. Office: 201, ‘Devavrata’, Sector - 17, Vashi, Navi Mumbai - 400 703  
Corp. Office: Strides House, Bannerghatta Road, Bangalore - 560076

K Priya: +91 95354 25418  
priya@fortunapr.com